Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Risk of breast cancer and family history of other cancers in first-degree relatives in Chinese women: a case control study

Authors: Wenbin Zhou, Qiang Ding, Hong Pan, Naping Wu, Mengdi Liang, Yaoyu Huang, Lin Chen, Xiaoming Zha, Xiaoan Liu, Shui Wang

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Few studies have systematically reported the relationship between the risk of breast cancer and family history of other cancers. This study was designed to systematically determine the relationship between breast cancer risk and family history of other cancers in first-degree relatives.

Methods

Between January 2006 and June 2011, 823 women diagnosed with breast cancer were included, and age-matched women diagnosed with benign breast disease were selected as controls. Family history of other cancers in first-degree relatives was recorded by trained reviewers. Multivariate logistic regression was applied to analyze the relationships.

Results

A family history of esophagus cancer (OR: 2.70, 95% CI: 1.11 – 6.57), lung cancer (OR: 2.49 95% CI: 1.10 – 5.65), digestive system cancer (OR: 1.79, 95% CI: 1.14 – 2.79) and any cancer (OR: 2.13, 95% CI: 1.49 – 3.04) in first-degree relatives was directly associated with increased breast cancer risk. In subgroup analysis, the risk of hormone receptor positive breast cancer was increased in subjects with a family history of lung cancer (OR: 3.37, 95% CI: 1.45 – 7.82), while the risk of hormone receptor negative breast cancer was increased in subjects with a family history of esophagus cancer (OR: 6.19, 95% CI: 2.30 – 16.71), uterus cancer (OR: 6.92, 95% CI: 1.12 – 42.89), digestive tract cancer (OR: 2.05, 95% CI: 1.03 – 4.10) and gynecology cancer (OR: 6.79, 95% CI: 1.46 – 31.65). Additionally, a significant increase in breast cancer was observed with a family history of digestive system cancer for subjects 50 y and younger (OR: 1.88, 95% CI: 1.03 – 3.43), not for subjects 50 y older (OR: 1.67, 95% CI: 0.86 – 3.25).

Conclusions

Breast cancer aggregates in families with several types of cancer especially for digestive system cancer. The influence of a family history of other cancers seems more likely to be limited to hormone receptor negative breast cancer.
Literature
1.
Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006, 24 (14): 2137-2150. 10.1200/JCO.2005.05.2308.CrossRefPubMed
2.
DeSantis C, Siegel R, Bandi P, Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin. 2011, 61 (6): 409-418.CrossRefPubMed
3.
Ghiasvand R, Maram ES, Tahmasebi S, Tabatabaee SH: Risk factors for breast cancer among young women in southern Iran. Int J Cancer. 2011, 129 (6): 1443-1449. 10.1002/ijc.25748.CrossRefPubMed
4.
Negri E, Bertuccio P, Talamini R, Franceschi S, Montella M, Giacosa A, Pelucchi C, La Vecchia C: A history of cancer in the husband does not increase the risk of breast cancer. Int J Cancer. 2006, 118 (12): 3177-3179. 10.1002/ijc.21754.CrossRefPubMed
5.
Colditz GA, Kaphingst KA, Hankinson SE, Rosner B: Family history and risk of breast cancer: nurses’ health study. Breast Cancer Res Treat. 2012, 133 (3): 1097-1104. 10.1007/s10549-012-1985-9.CrossRefPubMedPubMedCentral
6.
Ready K, Arun B: Clinical assessment of breast cancer risk based on family history. J Natl Compr Canc Netw. 2010, 8 (10): 1148-1155.PubMed
7.
Smith RP, Ni X, Muram D: Breast cancer risk assessment: positive predictive value of family history as a predictor of risk. Menopause. 2011, 18 (6): 621-624. 10.1097/gme.0b013e3182027963.CrossRefPubMed
8.
Negri E, Braga C, La Vecchia C, Franceschi S, Parazzini F: Family history of cancer and risk of breast cancer. Int J Cancer. 1997, 72 (5): 735-738. 10.1002/(SICI)1097-0215(19970904)72:5<735::AID-IJC5>3.0.CO;2-T.CrossRefPubMed
9.
Anderson DE, Badzioch MD: Familial breast cancer risks. effects of prostate and other cancers. Cancer. 1993, 72 (1): 114-119. 10.1002/1097-0142(19930701)72:1<114::AID-CNCR2820720122>3.0.CO;2-0.CrossRefPubMed
10.
Parazzini F, La Vecchia C, Negri E, Franceschi S, Tozzi L: Family history of breast, ovarian and endometrial cancer and risk of breast cancer. Int J Epidemiol. 1993, 22 (4): 614-618. 10.1093/ije/22.4.614.CrossRefPubMed
11.
Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H: Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ. 1992, 305 (6858): 855-857. 10.1136/bmj.305.6858.855.CrossRefPubMedPubMedCentral
12.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295 (21): 2492-2502. 10.1001/jama.295.21.2492.CrossRefPubMed
13.
Li CI, Malone KE, Daling JR: Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003, 163 (1): 49-56. 10.1001/archinte.163.1.49.CrossRefPubMed
14.
Chu KC, Anderson WF: Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res Treat. 2002, 74 (3): 199-211. 10.1023/A:1016361932220.CrossRefPubMed
15.
Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW: Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer. 2001, 92 (1): 37-45. 10.1002/1097-0142(20010701)92:1<37::AID-CNCR1289>3.0.CO;2-F.CrossRefPubMed
16.
Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE: Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol. 2009, 169 (10): 1251-1259. 10.1093/aje/kwp036.CrossRefPubMedPubMedCentral
17.
Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE: Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004, 96 (3): 218-228. 10.1093/jnci/djh025.CrossRefPubMed
18.
Hines LM, Risendal B, Slattery ML, Baumgartner KB, Giuliano AR, Byers T: Differences in estrogen receptor subtype according to family history of breast cancer among Hispanic, but not non-Hispanic White women. Cancer Epidemiol Biomarkers Prev. 2008, 17 (10): 2700-2706. 10.1158/1055-9965.EPI-08-0504.CrossRefPubMedPubMedCentral
19.
Palmer JR, Boggs DA, Adams-Campbell LL, Rosenberg L: Family history of cancer and risk of breast cancer in the Black Women’s Health Study. Cancer Causes Control. 2009, 20 (9): 1733-1737. 10.1007/s10552-009-9425-9.CrossRefPubMedPubMedCentral
20.
Strum WB: Impact of a family history of colorectal cancer on age at diagnosis, anatomic location, and clinical characteristics of colorectal cancer. Int J Gastrointest Cancer. 2005, 35 (2): 121-126. 10.1385/IJGC:35:2:121.CrossRefPubMed
21.
Cassidy A, Myles JP, Duffy SW, Liloglou T, Field JK: Family history and risk of lung cancer: age-at-diagnosis in cases and first-degree relatives. Br J Cancer. 2006, 95 (9): 1288-1290. 10.1038/sj.bjc.6603386.CrossRefPubMedPubMedCentral
22.
Yu KD, Li JJ, Di GH, Wu J, Shen ZZ, Shao ZM: A straightforward but not piecewise relationship between age and lymph node status in Chinese breast cancer patients. PLoS One. 2010, 5 (6): e11035-10.1371/journal.pone.0011035.CrossRefPubMedPubMedCentral
23.
Zhou W, He Z, Xue J, Wang M, Zha X, Ling L, Chen L, Wang S, Liu X: Molecular subtype classification is a determinant of non-sentinel lymph node metastasis in breast cancer patients with positive sentinel lymph nodes. PLoS One. 2012, 7 (4): e35881-10.1371/journal.pone.0035881.CrossRefPubMedPubMedCentral
24.
Wang M, Zhou W, Zhao Y, Xia T, Zha X, Ding Q, Liu X, Ling L, Chen L, Wang S: A novel finding of sentinel lymphatic channels in early stage breast cancer patients: which may influence detection rate and false-negative rate of sentinel lymph node biopsy. PLoS One. 2012, 7 (12): e51226-10.1371/journal.pone.0051226.CrossRefPubMedPubMedCentral
25.
Pan H, Xia K, Zhou W, Xue J, Liang X, Cheng L, Wu N, Liang M, Wu D, Ling L, Ding Q, Chen L, Zha X, Liu X, Wang S: Low serum creatine kinase levels in breast cancer patients: a case-control study. PLoS One. 2013, 8 (4): e62112-10.1371/journal.pone.0062112.CrossRefPubMedPubMedCentral
26.
Manfrin E, Mariotto R, Remo A, Reghellin D, Falsirollo F, Dalfior D, Bricolo P, Piazzola E, Bonetti F: Benign breast lesions at risk of developing cancer–a challenging problem in breast cancer screening programs: five years’ experience of the Breast Cancer Screening Program in Verona (1999–2004). Cancer. 2009, 115 (3): 499-507. 10.1002/cncr.24038.CrossRefPubMed
27.
Hemminki K, Sundquist J, Brandt A: Do discordant cancers share familial susceptibility?. Eur J Cancer. 2012, 48 (8): 1200-1207. 10.1016/j.ejca.2011.09.017.CrossRefPubMed
28.
Turati F, Edefonti V, Bosetti C, Ferraroni M, Malvezzi M, Franceschi S, Talamini R, Montella M, Levi F, Dal Maso L, Serraino D, Polesel J, Negri E, Decarli A, La Vecchia C: Family history of cancer and the risk of cancer: a network of case-control studies. Ann Oncol. 2013, 24 (10): 2651-2656. 10.1093/annonc/mdt280.CrossRefPubMed
29.
Pohl H, Wrobel K, Bojarski C, Voderholzer W, Sonnenberg A, Rosch T, Baumgart DC: Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol. 2013, 108 (2): 200-207. 10.1038/ajg.2012.387.CrossRefPubMed
30.
Yu XF, Wang YQ, Zou J, Dong J: A meta-analysis of the effects of energy intake on risk of digestive cancers. World J Gastroenterol. 2012, 18 (48): 7362-7370. 10.3748/wjg.v18.i48.7362.CrossRefPubMedPubMedCentral
31.
Chen HM, Yu YN, Wang JL, Lin YW, Kong X, Yang CQ, Yang L, Liu ZJ, Yuan YZ, Liu F, Wu JX, Zhong L, Fang DC, Zou W, Fang JY: Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. Am J Clin Nutr. 2013, 97 (5): 1044-1052. 10.3945/ajcn.112.046607.CrossRefPubMed
32.
Petracci E, Decarli A, Schairer C, Pfeiffer RM, Pee D, Masala G, Palli D, Gail MH: Risk factor modification and projections of absolute breast cancer risk. J Natl Cancer Inst. 2011, 103 (13): 1037-1048. 10.1093/jnci/djr172.CrossRefPubMedPubMedCentral
33.
Jiang X, Castelao JE, Chavez-Uribe E, Fernandez Rodriguez B, Celeiro Munoz C, Redondo CM, Pena Fernandez M, Novo Dominguez A, Pereira CD, Martinez ME, García-Caballero T, Fraga Rodriguez M, Antúnez J, Carracedo A, Forteza-Vila J, Gago-Dominguez M: Family history and breast cancer hormone receptor status in a Spanish cohort. PLoS One. 2012, 7 (1): e29459-10.1371/journal.pone.0029459.CrossRefPubMedPubMedCentral
34.
Shannon C, Smith IE: Breast cancer in adolescents and young women. Eur J Cancer. 2003, 39 (18): 2632-2642. 10.1016/S0959-8049(03)00669-5.CrossRefPubMed
35.
Nelson HD, Huffman LH, Fu R, Harris EL: Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005, 143 (5): 362-379. 10.7326/0003-4819-143-5-200509060-00012.CrossRefPubMed
36.
Habbe N, Langer P, Sina-Frey M, Bartsch DK: Familial pancreatic cancer syndromes. Endocrinol Metab Clin North Am. 2006, 35 (2): 417-430. 10.1016/j.ecl.2006.02.016. xiCrossRefPubMed
37.
Farrell C, Lyman M, Freitag K, Fahey C, Piver MS, Rodabaugh KJ: The role of hereditary nonpolyposis colorectal cancer in the management of familial ovarian cancer. Genet Med. 2006, 8 (10): 653-657. 10.1097/01.gim.0000241895.20390.c5.CrossRefPubMed
38.
Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Palmer C, Rapaport H, Nafa K, Ellis NA, Offit K: Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst. 2004, 96 (1): 68-70. 10.1093/jnci/djh006.CrossRefPubMed
39.
Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S, Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon W, Greenblatt M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers G, Pizzuti A, Vaccaro C, Redal MA, et al: Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007, 297 (21): 2360-2372. 10.1001/jama.297.21.2360.CrossRefPubMed
40.
Friedenson B: BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed. 2005, 7 (2): 60-PubMedPubMedCentral
41.
Ford D, Easton DF, Peto J: Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995, 57 (6): 1457-1462.PubMedPubMedCentral
42.
Parent ME, Ghadirian P, Lacroix A, Perret C: Accuracy of reports of familial breast cancer in a case-control series. Epidemiology. 1995, 6 (2): 184-186. 10.1097/00001648-199503000-00018.CrossRefPubMed
43.
Mai PL, Garceau AO, Graubard BI, Dunn M, McNeel TS, Gonsalves L, Gail MH, Greene MH, Willis GB, Wideroff L: Confirmation of family cancer history reported in a population-based survey. J Natl Cancer Inst. 2011, 103 (10): 788-797. 10.1093/jnci/djr114.CrossRefPubMedPubMedCentral
Metadata
Title
Risk of breast cancer and family history of other cancers in first-degree relatives in Chinese women: a case control study
Authors
Wenbin Zhou
Qiang Ding
Hong Pan
Naping Wu
Mengdi Liang
Yaoyu Huang
Lin Chen
Xiaoming Zha
Xiaoan Liu
Shui Wang
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-662

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents

Research article

Nasopharyngeal carcinoma with paranasal sinus invasion: the prognostic significance and the evidence-based study basis of its T-staging category according to the AJCC staging system

Research article

Differential knockdown of TGF-β ligands in a three-dimensional co-culture tumor- stromal interaction model of lung cancer

Research article

Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region

Research article

Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

Technical advance

Bronchoscopic intratumoral injection of tranexamic acid to prevent excessive bleeding during multiple forceps biopsies of lesions with a high risk of bleeding: a prospective case series
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits